Ernexa Therapeutics Announces Its Preclinical Data From Its ERNA-101 Candidate Demonstrates 100% Long-Term Survival In Syngeneic Ovarian Cancer Models

Benzinga Newsdesk www.benzinga.com Positive 94.7%